Nitrous Nation: A Party Drug Endures

For decades, nitrous oxide has been widespread at raves and music festivals, used as a quick buzz. The drug doesn’t have the death toll of the opiate disaster or the widespread popularity of marijuana, but it’s widely sold — legally — all over the country, though its consumption outside medical facilities is illegal in many…

Details

MacKenzie Scott, Melinda Gates, Priscilla Chan: On Women Philanthropists

“The effort that goes into motivating volunteers and building community spirit can be dismissed as ‘merely’ sociable interchange, related to women’s gender roles and natural propensities, requiring no real skills,” wrote the study’s author, Arlene Kaplan Daniels. “Women who engaged in philanthropy were the behind-the-scenes volunteers, the unrecognized work,” said Debra Mesch, a professor of…

Details

Nivolumab effective treatment for malignant mesothelioma

(Singapore–January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST)– Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. Malignant mesothelioma is an intractable cancer, and no phase III trial has…

Details

Selected gene mRNA expression is not predictive of improved overall survival

(Singapore–January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST)– A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International…

Details

LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate

(Singapore–January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST)– Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International…

Details